GlycoSyn is a business unit of Callaghan Innovation, and specialises in the production of process intermediates and Active Pharmaceutical Ingredients (APIs), including under GMP. GlycoSyn’s world-class expertise in carbohydrate chemistry and its GMP manufacturing facility are in New Zealand, near the capital city of Wellington. From here, the company partners with clients in all corners of the globe. As small molecule specialists, GlycoSyn has built a distinguished track record in chemical and chemo-enzymatic synthesis. We have successfully applied this expertise to the development of enzyme inhibitors, dendrimer constructs, glycopolymers, and vaccine adjuvants in the treatment of cancers, rare diseases, and neurodegenerative diseases. Our expertise in Carbohydrate Chemistry began in the 1980’s with Drs Furneaux, Ferrier and Tyler. The team now includes over 50 PhD Chemists and Analysts with substantial publication records and outputs, including 4 compounds in clinical development. This enormous reservoir of carbohydrate and complex chemistry expertise is what makes GlycoSyn unique as a CRO/CDMO. Thanks to our links with the Ferrier Research Institute and Callaghan Innovation, we have the largest combined concentration of carbohydrate chemistry and cGMP manufacturing expertise in the world. Services • Contract Discovery and Medicinal Chemistry • Process Development & GMP manufacture • APIs for Preclinical & Clinical Trials • Analytical Development (Method Qualification & Validation as appropriate) • Metabolite Standards GMP Manufacture • Specialists in complex multi-step synthesis  30 year track record • cGMP manufacturing since 2003 • Licensed to manufacture medicines (PIC/S GMP Pt II, ICH Q7 equivalent)